MetabolismNews.net

Metabolism Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Xagena Salute

Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholester ...


The Phase 3 SPIRE-AI ( AutoInjector ) trial of the investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor ( PCSK9i ) Bococizumab administered with a pre-filled pen met its co-primary ...


New detailed data from the phase 3 GAUSS-3 ( Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 ) trial evaluating Evolocumab ( Repatha ) in patients with high cho ...


The composition of the gut microbiota and excessive ingestion of high-fat diets ( HFD ) are considered to be important factors for development of obesity. Researchers have described a coherent mec ...


Previous studies have suggested that Niacin treatment raises glucose levels in patients with diabetes mellitus and may increase the risk of developing diabetes. Researchers performed a meta-analysis ...


Alirocumab ( Praluent ) lowers cholesterol in patients with heterozygous familial hypercholesterolemia to levels unreachable with statins alone, according to results from four ODYSSEY trials. Final d ...


Inhibition of proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) has been intensively studied to lower low-density lipoprotein cholesterol ( LDL-C ) levels. The purpose of this meta-analysis ...


The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events ( HPS2-THRIVE ) showed that adding extended-release Niacin-Laropiprant ( ERN-LRPT ) to statin provided no incre ...


Despite current standard-of-care, many patients at high cardiovascular disease ( CVD ) risk still have elevated low-density lipoprotein cholesterol ( LDL-C ). Alirocumab ( Praluent ) is a fully huma ...


Phase 2b TULIP study results with CETP inhibitor, TA-8995, a drug in the field of dyslipidemia, were published in the Lancet. The peer-reviewed article is entitled Cholesterol ester transfer protein i ...


Results from ETC-1002-009, a phase 2b study evaluating the efficacy and safety of ETC-1002 ( Bempedoic acid ) compared with placebo in patients with hypercholesterolemia on stable statin therapy, were ...


Bococizumab is a humanized monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, which may be a potential therapeutic option for reducing low-density lipoprotein cholesterol ( LDL ...


A study has compared the efficacy [ low-density lipoprotein cholesterol ( LDL-C ) lowering ] and safety of Alirocumab ( Praluent ), a fully human monoclonal antibody to proprotein convertase subtilisi ...


The objective of a study was to evaluate the efficacy and safety of extended dosing with Mipomersen ( Kynamro ) in patients with familial hypercholesterolaemia taking maximally tolerated lipid-lowerin ...


One-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the phase 2 ( OSLER-1 ) and phase 3 ( OSLER-2 ) open-label extension studies of Evolocumab ( Repatha ), a ...